Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Erlangen-Nürnberg Medical School
Bicara Therapeutics
BioNTech SE
NRG Oncology
The Netherlands Cancer Institute
Cancer Research UK
Inhibrx Biosciences, Inc
Stanford University
University of British Columbia
Privo Technologies
Second Affiliated Hospital of Guangzhou Medical University
Sun Yat-sen University
Shanghai Jiao Tong University School of Medicine